The 38th European Association of Urology Annual Meeting (EAU23) was held in Milan, Italy, the world’s fashion capital, from March 10 to 13, 2023. The EAU annual conference is one of the most closely watched urology conferences in Europe and even globally, attracting over 15,000 urology experts worldwide every year. At this EAU conference, two kidney cancer-related studies from the team of Dr Kan Gong of Peking University First Hospital were selected for discussion. The research indicates that the age of first onset is an independent risk factor affecting the prognosis in patients with large fragment deletions of Von Hippel-Lindau (VHL) syndrome. These patients may benefit from tyrosine kinase inhibitor (TKI) treatment. Initial CD4+T cells and memory CD4+T cells may be specific immune cells infiltrating VHL syndrome-related kidney cancer, and their infiltration level is closely related to VHL protein expression and patient prognosis.
Abstract No.: A0345
Clinical Characteristics and Genotype-Phenotype Correlation of Patients with Large Fragment Deletion VHL Syndrome
This study found that In patients with large fragment deletions of VHL syndrome, familial generation and exon 2 status can influence the age of onset of related conditions. The age of first onset is an independent risk factor for overall survival prognosis in these patients. TKI treatment may be beneficial for these patients.
Abstract No.: A0344
Exploring Immune Cell Infiltration Characteristics of VHL Syndrome-Related Kidney Cancer
It found that initial CD4+T cells and memory CD4+T cells may be specific infiltrating immune cells in VHL syndrome-related kidney cancer. Their infiltration levels are closely associated with VHL protein expression and patient prognosis.
Dr. Kan Gong
Deputy Director of Peking University Urology Research Institute
